Inhibition of hepatic tumour necrosis factor-α attenuates the anandamide-induced vasoconstrictive response in cirrhotic rat livers

Liver International

Volumn 29, Issue 5, 2009, Pages 678-685

  Yang, Ying Ying ^a,b   Lee, Kuei Chuan ^a,b   Huang, Yi Tsau ^b   Lee, Fa Yauh ^a,b   Chau, Ga Yang ^a,b   Loong, Che Chuan ^a,b   Lin, Han Chieh ^a,b   Lee, Shou Dong ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Anandamide; Tumour necrosis factor ; Vasoconstriction

Indexed keywords

ANANDAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; INTERLEUKIN 6; THALIDOMIDE; THROMBOXANE SYNTHASE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY BLOOD FLOW; ARTICLE; BILE DUCT LIGATION; CONTROLLED STUDY; DOWN REGULATION; IMMUNOMODULATION; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER PERFUSION; MALE; NONHUMAN; PORTAL VEIN BLOOD PRESSURE; PROTEIN EXPRESSION; RAT; SUPERIOR MESENTERIC ARTERY; UPREGULATION; VASOCONSTRICTION;

ANIMALS; ARACHIDONIC ACIDS; DNA PRIMERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; LIVER; LIVER CIRRHOSIS, BILIARY; MICROCIRCULATION; POLYUNSATURATED ALKAMIDES; RATS; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STATISTICS, NONPARAMETRIC; THALIDOMIDE; TUMOR NECROSIS FACTOR-ALPHA; VASOCONSTRICTION;

EID: 64749116377     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2009.01983.x     Document Type: Article

References (46)

1. 1 receptors mediate the vasodilated state in advanced liver cirrhosis. Nat Med 2001; 7: 827-32.
2. 1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Hepatology 2007; 45: 543-4.
3. Varga K, Wanger JA, Bridgeb DT, Kunos G. Platelet and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension. FASEB J 1998; 12: 1035-44.
4. Mackie K, Stella N. Cannbinoid receptors and endocannabinoids: Evidence for new player. AAPS J 2006; 8: E298-300.
5. Gujral JS, Farhood A, Bajt ML, Jaeshke H. Neutrophils aggravate liver injury during obstructive cholestasis in bile duct-ligated mice. Hepatology 2003; 38: 355-63.
6. Wong F, Bernardi M, Balk R, et al. Sepsis in cirrhosis: Report on the 7th meeting of the international ascites club. Gut 2005; 54: 718-25.
7. Szabo G, Romics Jr L, Frendl G. Liver in sepsis and systemic inflammatory response syndrome. Clin Liver Dis 2002; 6: 1045-66.
8. 2 activity, and hepatic toxicity in rats with cirrhosis. J Hepatol 2000; 33: 376-81.
9. 2. J Hepatol 2007; 47: 228-38.
10. Goulis J, Patch D, Burroughs AK. Bacterial infection in the pathogenesis of variceal bleeding. Lancet 1999; 353: 139-42.
11. Rodriguez RE, Gonzalez RE, Santolaria FF, et al. Cytokines levels in acute alcoholic hepatitis: A sequential study. Drug Alcohol Depend 1995; 39: 23-7.
12. Larrea E, Garcia N, Qian C, Civiera MP, Prieto J. Tumor necrosis factor alpha gene expression and the response to interferon in chronic hepatitis C. Hepatology 1996; 23: 210-7.
13. Bradham CA, Plumpe J, Manns MP, Brenner DA, Trautwein C. Mechanisms of hepatic toxicity I. TNF-induced liver injury. Am J Physiol 1998; 275: G387-92.
14. Iimuro Y, Gallucci RM, Luster MI, Kono H, Thurman RG. Antibodies to tumor necrosis factor-α attenuate hepatic fibrosis and inflammation caused by chronic exposure to ethanol in the rat. Hepatology 1997; 26: 1530-7.
15. Keifer JA, Guttridge DC, Ashburner BP, Baldwin Jr AS. Inhibition of NF-kappa B activity by thalidomide through suppression of I kappa B kinase activity. J Biol Chem 2001; 276: 22382-7.
16. Enomoto N, Takei Y, Hirose M, et al. Thalidomide prevents alcoholic liver injury in rats through suppression of kupffer cell sensitization and TNF-α production. Gastroenterology 2002; 123: 291-300.
17. Mreira AL, Sampaio EP, Zmuidzinas A, et al. Thalidomide exert its inhibitory action on tumor necrosis factor-α by enhancing mRNA degradation. J Exp Med 1993; 177: 1675-80.
18. Ehrenpreis ED, Kane SV, Cohen LB, Cohen RD, Hanauer SB. Thalidomide therapy for patients with refractory Crohn's disease: An open-label trial. Gastroenterology 1999; 117: 1271-7.
19. Reyes-Teran G, Sirra-Madero JG, Martinez del Cerro V, et al. Effects of thalidomide on HIV-associated wasting syndrome: A randomized, double-blind, placebo-controlled clinical trial. AIDS 1996; 10: 1501-7.
20. Lopez-Talavera JC, Cadelina G, Olchowski J, Merrill W, Groszmann RJ. Thalidomide inhibits tumor necrosis factor-α, decrease nitric oxide synthesis and ameliorates the hyperdynamic circulatory syndrome in portal-hypertensive rats. Hepatology 1996; 23: 1616-21.
21. Muriel P, Fernandez-Martinez E, Perez-Alvarez V, et al. Thalidomide ameliorates carbon tetrachloride induced cirrhosis in rats. Eur J Gastroenterol Hepatol 2003; 15: 951-7.
22. Yeh TS, Ho YP, Huang SF, et al. Thalidomide salvages lethal hepatic necroinflammation and accelerates recovery from cirrhosis in rats. J Hepatol 2004; 41: 606-12.
23. Fernandez-Martinez E, Marales-Rios MS, Perez-Alvarez V, Muriel P. Effect of thalidomide and 3-phthalimido-3-(3,4-dimethoxyphenyl)-propanamide on bile duct obstruction-induced cirrhosis in the rat. Drug Dev Res 2001; 54: 209-18.
24. Yang YY, Lin HC, Huang YT, et al. Roles of anandamide in the hepatic microcirculation in cirrhotic rats. Am J Physiol 2006; 290: G328-34.
25. 1 cannabinoid receptor antagonism on livers of rats with biliary cirrhosis. Clin Sci 2007; 112: 533-42.
26. Lin HC, Huang YT, Wu HL, et al. Effect of sustained release lanreotide on hemodynamics in rats with portal vein stenosis. J Hepatol 1999; 31: 482-8.
27. Lin HC, Yu PC, Lee SD, et al. Effects of reserpine administration in two models of portal hypertension in rats. J Hepatol 1993; 19: 413-7.
28. Massey HD, McPherson RA. Cytokines and adhesion molecules. In: Henry JB, ed. Clinical Diagnosis and Management by Laboratory Methods, 20th edn. Phi l adelphia: Saunders, 2001; 914-26.
29. Knolle PA, Loser E, Protzer U, et al. Regulation of endotoxin-induced IL-6 production in liver sinusoidal endothelial cells and kupffer cells by IL-10. Clin Exp Immunol 1997; 107: 555-61.
30. May LT, Torcia G, Cozzolino F, et al. Interleukin-6 gene expression in human endothelial cells: RNA starts sites, multiple IL-6 proteins and inhibition of proliferation. Biochem Biophys Res Commun 1989; 159: 991-8.
31. Ala Y, Pally O, Favero J, et al. Hypoxia/reoxygenation stimulates endothelail cells to promote interleukin-1 and interleukin-6 production. Effects of free radical scavengers. Agents Actions 1992; 37: 134-9.
32. Sherlock S. Chronic hepatitis and cirrhosis. Hepatology 1984; 4: S25-8.
33. Ros J, Clária J, To-Figueras J, et al. Endogenous cannabinoids: A new system involved in the homeostasis of arterial pressure in experimental cirrhosis in the rat. Gastroenterology 2002; 122: 85-93.
34. Liu J, Bátkai S, Pacher P, et al. Lipopolysaccharide induces anandamide synthesis in macrophages via CD14/MAPK/phosphoinositide 3-kinase/NF-kappaB independently of platelet-activating factor. J Biol Chem 2003; 278: 45034-9.
35. 2 receptors as new therapeutic targets for liver diseases. Br J Pharmacol 2008; 153: 286-9.
36. 1 cannabinoid receptors in human vascular endothelial cells. Biochem J 2000; 346: 835-40.
37. Alberts B, Johnson A, Lewis J, et al. Signaling through G-protein-linked cell-surface receptors. In: Anderson MS, Dilernia B, Goatly B, eds. Molecular Biology of the Cell. Washington: Taylor and Francis, 2002; 853-70.
38. Graupera M, Garcia-Pagan JC, Abraldes JG, et al. Cyclooxygenase-derived products modulates the increased intrahepatic resistance of cirrhotic rat livers. Hepatology 2003; 37: 172-81.
39. Goodman LS, Gilman AG. The pharmacological basis of therapeutics. In: Morrow JD, Roberts Jr LJ, eds. Lipid-Derived Autocoids. New York: McGraw-Hill, 2001; 669-85.
40. Yazici Z, Folco GC, Drazen JM, Nigam S, Shimizu T. Advances in prostaglandin, leukotriene, and other bioactive research. In: Hinz B, Ramer R, Brune K, eds. Induction of COX-2 Expression by the Endocannabinoid Derivative R(+)-Methanandamide. New York: Kluwer Academic/Plenum, 2003; 145-52.
41. Kojima S, Sugiura T, Waku K, Kamilkawa Y. Contractile response to a cannabimimetic eicosanoid, 2-arachidonoylglycerol, of longitudinal smooth muscle from the guinea-pig distal colon in vitro. Eur J Pharmacol 2002; 444: 203-7.
42. Kozak KR, Crews BC, Morrow JD, et al. Metabolism of the endocannabinoids, 2-arachidonylglycerol and anandamide, into prostagladin, thromboxanes, and prostacyclin glycerol esters and ethanolamides. J Biol Chem 2002; 277: 44877-85.
43. 1 receptor. Br J Pharmacol 2006; 149: 898-908.
44. 2 in the liver. Gastroenterology 2005; 128: 742-55.
45. 2 receptor in cirrhotic rats. J Pharmacol Exp Ther 2008; 324: 475-83.
46. 1 cannabinoid receptor antagonism: A new strategy for the treatment of liver fibrosis. Nat Med 2006; 12: 671-6.